Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too

(MedPage Today) -- For patients with hematologic cancers, allogeneic hematopoietic stem-cell transplant with the advanced cell therapy omidubicel was associated with lower rates of non-relapse mortality and infection compared to myeloablative umbilical...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news